Thierry Buclin

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


505 publications

... | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | ...
2012
 
Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma.
Grouzmann E., Matter M., Bilz S., Herren A., Triponez F., Henzen C., Kim K.S., Zulewski H., Buclin T., Brakch N. et al., 2012. Journal of Clinical Endocrinology and Metabolism, 97 (8) pp. 2773-2781.
[DOI][WoS][Pmid][serval:BIB_15AEE025DDEF]
 
Pharmacokinetic (PK)-based dosage individualization of imatinib: evaluation of efficiency and clinical usefulness
Gotta V., Widmer N., Decosterd L.A., Montemurro M., Leyvraz S., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L. et al., 2012. dans 3rd Symposium of the Swiss Clinical Trial Organisation (SCTO), Personalised Medicine in Clinical Research.
[serval:BIB_10F3BBD6809D]
 
Pharmacovigilance [Pharmacovigilance].
Livio F., Renard D., Buclin T., 2012. Revue Médicale Suisse, 8 (324) pp. 116-119.
[Pmid][serval:BIB_D7E6ACB41846]
 
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M., Fayet-Mello A., Lubomirov R., Neely M., di Iulio J., Owen A., Boffito M., Cavassini M., Günthard H.F., Rentsch K. et al., 2012. Antimicrobial Agents and Chemotherapy, 56 (6) pp. 2959-2966.
[DOI][WoS][Pmid][serval:BIB_6052FCB27C8D]
 
Population pharmacokinetics in chronic myeloid leukaemia patients: observations under field-conditions
Gotta V., Bouchet S., Widmer N., Mahon F.-X., Molimard M., Buclin T., Csajka C., 2012. pp. 111S-112S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
[serval:BIB_E1C1BA8A0484]
Pragmatic approach for interpreting antiretroviral drug concentrations based on a systematic review of population pharmacokinetic studies
Arab-Alameddine M., Buclin T., Guidi M., Widmer N., Decosterd L.A., Csajka C., 2012. pp. Abstr. 2441 dans 21st Population Approach Group in Europe (PAGE) meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[URN][serval:BIB_3D75DE43C185]
 
Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study.
Panchaud A., Csajka C., Merlob P., Schaefer C., Berlin M., De Santis M., Vial T., Ieri A., Malm H., Eleftheriou G. et al., 2012. Journal of Clinical Pharmacology, 52 (12) pp. 1844-1851. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A2D63B38436E]
 
Prevalence and determinants of QT interval prolongation in medical inpatients.
Pasquier M., Pantet O., Hugli O., Pruvot E., Buclin T., Waeber G., Aujesky D., 2012. Internal Medicine Journal, 42 (8) pp. 933-940.
[DOI][WoS][Pmid][serval:BIB_16A81A8611D3]
 
Prevalence, incidence and indications of hypno-sedative treatments in hospitalized patients aged 75 and older
Von Rohr T.R., Rochat S., Monod S., Buela C., Buclin T., Renard D., Csajka C., 2012. p. 228 dans 40th International Symposium on Clinical Pharmacy (ESCP), Clinical Pharmacy: Connecting Care and Outcomes, International Journal of Clinical Pharmacy.
[WoS][serval:BIB_B98C3D34DCC1]
Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions
Gotta V., Bouchet S., Widmer N., Mahon F.X., Molimard M., Buclin T., Csajka C., 2012. pp. Abstr. 2504 dans 21st Population Approach Group in Europe (PAGE) Meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[URN][serval:BIB_1B447D1B4DAA]
 
Safe and effective variability-a criterion for dose individualization.
Holford N.H., Buclin T., 2012. Therapeutic Drug Monitoring, 34 (5) pp. 565-568. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_961E4C3BFB2C]
 
Syndrome sérotoninergique: mise au point et revue des cas annoncés en Suisse [Serotonin syndrome: review and case series from the Swiss pharmacovigilance system].
Chassot M., Munz T., Livio F., Buclin T., 2012. Revue Médicale Suisse, 8 (360) pp. 2086-2090.
[Pmid][serval:BIB_9A9E62270B8A]
 
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2012. Clinical Pharmacokinetics, 51 (3) pp. 187-201. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2ED734507B5B]
 
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: A clinical pharmacology laboratory perspective
Decosterd L.A., Dahmane E., Neeman M., Buclin T., Csajka C., Haouala A., Widmer N., 2012. pp. 197-250 dans Xu Q.A, Madden T.L. (eds.) LC-MS in drug bioanalysis chap. 9, Springer.
[DOI][serval:BIB_D2C7505A3942]
 
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective oestrogen receptor modulators: A clinical pharmacology laboratory perspective
Decosterd LA Dahmane E Neeman M Buclin T Csajka C Haouala A Widmer N, 2012. pp. 197-250 dans LC-MS in Drug Bioanalysis, Springer.
[DOI][serval:BIB_66D3AE3FFDC2]
Utilisation des laxatifs à l'Hôpital
Dao Kim, Renard Delphine, Livio Françoise, Buclin Thierry, De Giorgi I, 2012. GSASA Journal 26 pp. 27-31.
[URN][serval:BIB_AEFD6225CB20]
 
Vancomycin exposure from active calcium sulfate bone filler
Livio F., Guidi M., Wahl P., Gautier E., Prod'Hom G., Buclin T., Csajka T., 2012. pp. 112S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
[serval:BIB_CDC4660C6308]
2011
Traitement et prophylaxie de la Maladie ThromboEmbolique Veineuse (MTEV)
Centre hospitalier universitaire vaudois, Policlinique médicale universitaire (Lausanne) , 2011/05. 2 p..
[URN][serval:BIB_EFE579EC6162]
 
Effets du cannabis sur les fumeurs occasionnels
Giroud C., Battistella G., Thomas A., Maeder P., Mall J.F., Annoni J.M., Appenzeller M., Buclin T., Staub C., Mangin P. et al., 2011/03., Société Française de Toxicologie Analytique (SFTA) pp. S1-8 dans Société Française de Toxicologie Analytique (SFTA) (eds.) Annales de toxicologie analytique, EDP Sciences.
[serval:BIB_8A0FEF7487E0]
 
Evaluation of risk perception related to drug use during pregnancy: a swiss survey
Jaquet A., Winterfeld U, Meyer Y., Buclin T., Csajka C., Panchaud A., 2011/02. p. 260 dans Reproductive Toxicology. Peer-reviewed.
[serval:BIB_5671B2BB58B2]
Additifs alimentaires et troubles de l’attention/hyperactivité chez l’enfant
Diezi Manuel, Buclin Thierry, Diezi Jacques, 2011. Paediatrica, 22 (5) pp. 12-15.
[URN][serval:BIB_B38222B6B682]
 
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
Arab-Alameddine M., Décosterd L.A., Buclin T., Telenti A., Csajka C., 2011. Expert Opinion On Drug Metabolism and Toxicology, 7 (5) pp. 609-622.
[DOI][WoS][Pmid][serval:BIB_844DA409294E]
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A., Buclin T., Franc C., Colombo S., Cruchon S., Guignard N., Biollaz J., Telenti A., Decosterd L.A., Cavassini M., 2011. Journal of Antimicrobial Chemotherapy, 66 (7) pp. 1573-1581.
[URN][DOI][WoS][Pmid][serval:BIB_525AF0812F4D]
Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy.
Buclin T., Telenti A., Perera R., Csajka C., Furrer H., Aronson J.K., Glasziou P.P., 2011. Plos One, 6 (4) pp. e18578.
[URN][DOI][WoS][Pmid][serval:BIB_721ABA6D07F9]
 
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
Haouala A., Widmer N., Duchosal M.A., Montemurro M., Buclin T., Decosterd L.A., 2011. Blood, 117 (8) pp. e75-e87. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E62C33C9D4C7]
 
Evaluation of risk perception related to drug use during pregnancy: a Swiss survey
Jaquet A., Winterfeld U., Meyer Y., Buclin T., Csajka C., Panchaud A., 2011. pp. 422-423 dans 39th ESCP European Symposium on Clinical Pharmacy and 13th SFPC Congress: Clinical Pharmacy at the Front Line of Innovations, International Journal of Clinical Pharmacy. Peer-reviewed.
[WoS][serval:BIB_9D071EE1F834]
 
How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data.
Lasserson D.S., Buclin T., Glasziou P., 2011. Heart, 97 (21) pp. 1771-1775.
[DOI][WoS][Pmid][serval:BIB_7FCFD14D4384]
 
How to Improve the Use of Proton Pump Inhibitors
Hodel M., Pauchet A., Buclin T., Mottet C., Gloor S., Guyot C., Biolat J., Chtioui H., Genne D., 2011. p. 164 dans 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Basic & Clinical Pharmacology & Toxicology. Peer-reviewed.
[WoS][serval:BIB_FB6C35CE2DC8]
 
Improvement of therapeutic drug monitoring of imatinib by Bayesian prediction of trough levels. Personalized drug dosage
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. p. 478 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
[DOI][WoS][serval:BIB_CEAB03974A49]
 
Need of reduced and harmonized bureaucracy in multi-centre clinical research - a case-report from a Swiss trial
Gotta V., Vallotton L., Widmer N., Buclin T., 2011. p. 7 dans 2011 Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology, British Journal of Clinical Pharmacology. Peer-reviewed.
[DOI][WoS][serval:BIB_71C7368FC6E5]
 
P-glycoprotein modulation by valspodar and cyclosporin does not increase tumor uptake of doxorubicin administered via isolated lung perfusion to rats bearing sarcoma lung metastases.
Kuemmerle A., Yan H., Krueger T., Buclin T., Braissant O., Henry H., Ris H.B., Decosterd L.A., 2011. Anticancer Research, 31 (6) pp. 2121-2128.
[WoS][Pmid][serval:BIB_B8D0A4E8CC76]
 
Personalized drug dosage: Monitoring of imatinib concentration with a Bayesian interpretation tool
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. dans Nano-Tera Annual Plenary Meeting.
[serval:BIB_D2ECCF2765CA]
 
Pharmacovigilance [Pharmacovigilance update].
Livio F., Biollaz J., Buclin T., 2011. Revue Médicale Suisse, 7 (277) pp. 71-74.
[Pmid][serval:BIB_868302B96C75]
 
Pregnancy outcome following maternal exposure to statins: a multicenter prospective study
Winterfeld U., Panchaud A., Merlob P., Rothuizen L., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M., Pistelli A. et al., 2011. p. 32 dans 2011 Joint Annual Meeting of the German, Swiss, and Austrian Societies for Clinical Pharmacology and Toxicology, British Journal of Clinical Pharmacology. Peer-reviewed.
[WoS][serval:BIB_356C95ABEEAB]
 
Pregnancy Outcome Following Maternal Exposure To Statins: A Multicenter Prospective Study
Winterfeld U., Panchaud A., Merlob P., Rothuizen L., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M., Pistelli A. et al., 2011. p. 142 dans 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Basic & Clinical Pharmacology & Toxicology. Peer-reviewed.
[WoS][serval:BIB_097345A56E49]
 
Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.
Grouzmann E., Bigliardi P., Appenzeller M., Pannatier A., Buclin T., 2011. Biological Chemistry, 392 (3) pp. 217-221.
[DOI][WoS][Pmid][serval:BIB_DE9CEF3B5B9F]
 
Successful efavirenz dose reduction guided by therapeutic drug monitoring.
Fayet Mello A., Buclin T., Decosterd L.A., Delhumeau C., di Iulio J., Fleurent A., Schneider M.P., Cavassini M., Telenti A., Hirschel B. et al., 2011. Antiviral Therapy, 16 (2) pp. 189-197.
[DOI][Pmid][serval:BIB_AC2598E4B289]
 
Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material.
Wahl P., Livio F., Jacobi M., Gautier E., Buclin T., 2011. Archives of Orthopaedic and Trauma Surgery, 131 (5) pp. 657-662.
[DOI][WoS][Pmid][serval:BIB_DCE890EC0F53]
 
The Authors' reply to "Mistaken conclusion"
Lasserson D.S., Buclin T., Glasziou P., 2011. Heart, 97 (24) pp. 2091-2092.
[DOI][WoS][serval:BIB_3BB1A18F0C35]
 
Traitements de fer: preuves de l'efficacité et bonne pratique clinique [Iron therapy: proof of efficacy and good clinical practice].
Renard D., Favrat B., Livio F., Buclin T., 2011. Revue Médicale Suisse, 7 (292) pp. 923-927.
[Pmid][serval:BIB_CBF2C240C020]
 
Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.
Buclin T., Widmer N., Biollaz J., Decosterd L.A., 2011. Lancet Oncology, 12 (1) pp. 9-11. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_15E65DE45ADE]
2010
 
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R., di Iulio J., Fayet A., Colombo S., Martinez R., Marzolini C., Furrer H., Vernazza P., Calmy A., Cavassini M. et al., 2010. Pharmacogenetics and Genomics, 20 (4) pp. 217-230.
[DOI][WoS][Pmid][serval:BIB_F0BE883DE124]
 
An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E., Mercier T., Zanolari B., Cruchon S., Guignard N., Buclin T., Leyvraz S., Zaman K., Csajka C., Decosterd L.A., 2010. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 878 (32) pp. 3402-3414.
[DOI][WoS][Pmid][serval:BIB_70F932215581]
 
Cannabinoids time-profiles, subjective and clinical effects, simulating driving capability after smoking a joint made of neat cannabis containing 11% THC
Giroud C., Thomas A., Battistella G., Maeder P., Mall J.F., Annoni J.M., Appenzeller M., Buclin T., Staub C., Mangin P. et al., 2010. dans SOFT 2010, Annual Meeting of the Society of Forensic Toxicologists. Peer-reviewed.
[serval:BIB_812371C1EA17]
 
Cardiovascular drug interactions with tyrosine kinase inhibitors
Haouala A., Widmer N., Montemurro M., Buclin T., Decosterd L., 2010. Cardiovascular Medicine, 13 (5) pp. 147-154. Peer-reviewed.
[serval:BIB_C7693B91F4FA]
 
Determination of oseltamivir and oseltamivir carboxylate in human plasma by liquid chromatography-tandem mass spectrometry
Aouri M., Zanolari B., Meylan P., Ivanyuk A., Buclin T., Decosterd L.A., Widmer N., 2010. pp. 25S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_715A74AC0128]
 
Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma.
Grouzmann E., Drouard-Troalen L., Baudin E., Plouin P.F., Muller B., Grand D., Buclin T., 2010. European Journal of Endocrinology / European Federation of Endocrine Societies, 162 (5) pp. 951-960.
[DOI][WoS][Pmid][serval:BIB_2BF86A335F41]
 
Evaluation of the impact of a therapeutic drug monitoring program in a Swiss University Hospital
Fernandez S., Widmer N., Buclin T., Biollaz J., Csajka C., 2010. pp. 283-284 dans ESCP-GSASA, 38th Symposium on Clinical Pharmacy, 30 years of clinical pharmacy : a bright future ahead, Pharmacy World and Science. Peer-reviewed.
[WoS][serval:BIB_16C92C4C7410]
 
Feasibility of Therapeutic Drug Monitoring (TDM) for Imatinib: Preliminary considerations on the dosage adjustment approach for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 90S dans 78. Jahresversammlung der Schweizerischen Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_FCE60B11AFF2]
 
Ganciclovir exposure under a 450mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study.
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Meylan P.R., 2010. Clinical Transplantation, 24 (6) pp. 794-800.
[DOI][WoS][Pmid][serval:BIB_4C94E197C48C]
 
Hypertension. Angio-oedème sous inhibition de l'enzyme de conversion de l'angiotensine et de la dipeptidyl-peptidase-4 [Angioedema during ACE and DPP-4 inhibition]
Waeber B., Buclin T., Grouzmann E., 2010. Revue Médicale Suisse, 6 (231) pp. 28-31.
[Pmid][serval:BIB_E59B27F760F0]
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
Widmer N., Decosterd L.A., Csajka C., Montemurro M., Haouala A., Leyvraz S., Buclin T., 2010. British Journal of Cancer, 102 (7) pp. 1198-1199. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EF7EF608D142]
Impact of cannabis inhalation on driving skills in occasional smokers
Thomas A., Battistella G., Maeder P., Mall J.F., Annoni J.M., Chtioui H., Appenzeller M., Buclin T., Staub C., Mangin P. et al., 2010. dans Tri-Annual Meeting of the International Council on Alcohol, Drugs and Traffic Safety.
[URN][serval:BIB_41DA66E03DB4]
 
Mapping the impact of cannabis on driving skills in occasional smokers. 84 MT-PM cognition and attention. Executive Function
Battistella G., Maeder P., Thomas A., Mall J.F., Annoni J.M., Appenzeller M., Favrat B., Chtioui H., Buclin T., Staub C. et al., 2010. dans OHBM 2010, 16th Annual Meeting of the Organization for Human Brain Mapping.
[serval:BIB_4BF6064FB518]
 
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Widmer N., Meylan P., Ivanyuk A., Aouri M., Decosterd L.A., Buclin T., 2010. Clinical Pharmacokinetics, 49 (11) pp. 741-765. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_499C0C125884]
 
Pharmacovigilance update [Pharmacovigilance update]
Livio F., Ivanyuk A., Biollaz J., Rothuizen L., Buclin T., 2010. Revue Médicale Suisse, 6 (232) pp. 128-131.
[Pmid][serval:BIB_6D790D62BAB3]
 
Pregnancy outcome after maternal exposure to statins: a multicenter prospective study
Winterfeld U., Panchaud A., Merlob P., Cuppers-Maarschalkerweerd B., Vial T., Stephens S., Clementi M., De Santis M., Pistelli A., Berlin M. et al., 2010. dans 21st Annual Meeting of the European Network Teratogen Information Services (ENTIS).
[serval:BIB_A6F9F6CDE49A]
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
Zaman K., Dahmane E., Perey L., Buclin T., Berthod G., Bodmer A., Galmiche M., Leyvraz S., Eap C., Csajka C. et al., 2010. dans 33rd Annual San Antonio Breast Cancer Symposium.
[URN][serval:BIB_34EABEDF4890]
 
Rapid occurrence of depression following addition of sodium oxybate to modafinil.
Rossetti A.O., Heinzer R.C., Tafti M., Buclin T., 2010. Sleep Medicine, 11 (5) pp. 500-501. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C6A89BF8D880]
 
siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors.
Haouala A., Rumpold H., Untergasser G., Buclin T., Ris H.B., Widmer N., Decosterd L.A., 2010. Drug Metabolism Letters, 4 (2) pp. 114-119. Peer-reviewed.
[Pmid][serval:BIB_EC32BB42AF84]
 
Statines et effets indésirables musculaires [Statins and muscular side-effects]
Brosteaux C., Ruiz J., Buclin T., Kuntzer T., Rodondi N., 2010. Revue Médicale Suisse, 6 (239) pp. 510-517. Peer-reviewed.
[Pmid][serval:BIB_CCDC48850EED]
Suivi thérapeutique de l'imatinib
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. Forum Medical Suisse, 10 (23) pp. 403-406. Peer-reviewed.
[URN][serval:BIB_FE549E7D44DF]
 
Therapeutic Drug Monitoring (TDM) of Imatinib: Effectiveness of Bayesian dose adjustment for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 28S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_84C101628359]
Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet Nancy, Manuel Oriol, Lamoth Frederic, Venetz Jean-Pierre, Sahli Roland, Decosterd Laurent A., Buclin Thierry, Pascual Manuel, Meylan Pascal, 2010. BMC Infectious Diseases, 10 p. 2.
[URN][DOI][WoS][Pmid][serval:BIB_1123642915A2]
2009
Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance.
Hodel E.M., Kabanywanyi A.M., Malila A., Zanolari B., Mercier T., Beck H.P., Buclin T., Olliaro P., Decosterd L.A., Genton B., 2009/12/14. PloS one, 4 (12) pp. e8184. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6BC8340814EF]
Tamoxifen metabolism and the impact of Tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients
Dahmane Elyes, Csajka Chantal, Decosterd Laurent, Mercier Thomas, Zanolari Boris, Eap Chin, Buclin Thierry, Galmiche Marie, Zaman Khalil, 2009/09. dans ''Frontiers in drug discovery and development'' : 24ème séminaire, 3ème cycle, en sciences pharmaceutiques.
[URN][serval:BIB_646DE6013BB6]
 
Acute effects of cannabis smoking on skills related to driving in occasional and heavy smokers
Giroud C., Battistella G., Buclin T., Mall JF., Thomas P., Favrat B., Mangin P., Maeder P., Fornari E., 2009/03. dans Lausanne, CHUV, CIBM-MR Research Meeting. March 16th. Oral presentation.
[serval:BIB_C9B14BE4087C]
 
"Iatrogenicity cascade": doing harm by treating harm?
Wagner C.C., Biollaz J., Zeitlinger M., Buclin T., 2009. Wiener Medizinische Wochenschrift, 159 (1-2) pp. 53-57.
[DOI][Pmid][serval:BIB_5330C6EC326A]
 
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
Fayet A., Béguin A., Zanolari B., Cruchon S., Guignard N., Telenti A., Cavassini M., Günthard H.F., Buclin T., Biollaz J. et al., 2009. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 877 (11-12) pp. 1057-1069.
[DOI][WoS][Pmid][serval:BIB_C3A49D552F26]
A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites
Kuemmerle A., Decosterd L. A., Buclin T., Liénard D., Stupp R., Chassot P. G., Mosimann F., Lejeune F., 2009. Cancer Chemotherapy and Pharmacology, 63 (2) pp. 331-341. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BD2D72C44FA2]
 
Acute Effects of Cannabis Smoking on Skills Related to Driving : an fMRI Study
Fornari E., Maeder P., Chtioui H., Thomas A., Appenzeller M., Favrat B, Buclin T., Staub C., Mangin P., Giroud C., 2009. pp. S179 dans OHBM 2009, 15th Annual Meeting of the Organization for Human Brain Mapping, NeuroImage. Peer-reviewed.
[DOI][serval:BIB_4CAC1327D422]
 
Adaptation of clinical practice guidelines on major depressive disorders in the general hospital: an update.
Voellinger R., Berney A., Burnand B., Stiefel F., Depression Development Group, 2009. Journal of Psychosomatic Research, 66 (4) pp. 353-354. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B6F674329F5A]
 
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.
Grouzmann E., Livio F., Buclin T., 2009. Hypertension, 54 (3) pp. 468-470. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A7BA8C35583C]
Blood cannabinoids levels and effects on cognitive performance and behavior as a function of joint smoking procedure and inhalation technique
Giroud Christian, Favrat Bernard, Thomas Aurélien, Battistella Giovanni, Mall Jean-Frédéric, Appenzeller Monique, Lauer Estelle, Buclin Thierry, Fornari Eleonora, Maeder Philippe et al., 2009. pp. S12 dans SOFT 2009 Annual Meeting, Society of Forensic Toxicologists. Peer-reviewed.
[URN][serval:BIB_5B36EC6FE483]
Cannabis intoxication with perceptual disturbances under clinical setting : O44
Giroud Christian, Thomas Aurélien, Mall Jean-Frédéric, Favrat Bernard, Appenzeller Monique, Buclin Thierry, Fornari Eleonara, Battistella Giovanni, Maeder Philippe, Staub Christian et al., 2009. p. 22 dans 47th Annual Meeting of the International Association of Forensic Toxicologists, Annales de Toxicologie Analytique. Peer-reviewed.
[URN][serval:BIB_179808DA4F51]
 
Codeine and breastfeeding: cases and STIS position
Panchaud A., Buclin T., 2009. dans 2nd Annual Meeting of the Swiss Association for Perinatal Pharmacology.
[serval:BIB_3C6F9292E4C4]
 
Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplant recipients: a prospective study : P125
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L., Buclin T., Meylan P., 2009. pp. 32S-33S dans Joint Annual Congress of the Swiss Society for Allergology and Immunology and the Swiss Society for Infectious Diseases, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_80EADAB09A91]
 
Ganciclovir Exposure under a 450 mg Daily Dosage of Valganciclovir for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients.
Manuel Oriol, Pascual Manuel, Perrottet Nancy, Lamoth Frederic, Venetz Jean-Pierre, Decosterd Laurent, Buclin Thierry, Meylan Pascal R., 2009. p. 249 dans 9th Joint Meeting of the American Society of Transplant Surgeon and of the American Society of Transplantation, American Journal of Transplantation. Peer-reviewed.
[WoS][serval:BIB_18DA47E61C5B]
 
High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction.
Lamoth F., Erard V., Asner S., Buclin T., Calandra T., Marchetti O., 2009. International Journal of Antimicrobial Agents, 34 (4) pp. 386-388.
[DOI][WoS][Pmid][serval:BIB_E23443E778F9]
Imipenem underdosing as a cause of persistent neutropenic fever?
Lamoth F., Buclin T., Pascual A., Calandra T., Marchetti O., 2009. Journal of Antimicrobial Chemotherapy, 64 (3) pp. 665-667.
[URN][DOI][WoS][Pmid][serval:BIB_8C7E736FBB7C]
 
Méthylphénidate et abus
Livio F., Rauber-Lüthy C., Biollaz J., Holzer L., Winterfeld U., Buclin T., 2009. Paediatrica : Bulletin der Schweizerischen Gesellschaft für Pädiatrie (SGP) = Bulletin de la Société suisse de pédiatrie (SSP), 20 (5) pp. 41-44.
[serval:BIB_652ACBB6A3FD]
 
Neuroimaging acute effects of cannabis smoking on skills related to driving with fMRI : results of a pilot study : V7
Giroud Christian, Thomas Aurélien, Chtioui Haithem, Appenzeller Monique, Favrat Bernard, Buclin Thierry, Staub Christian, Mangin Patrice, Maeder Philippe, Fornari Eleonora, 2009. p. 89 dans Pragst F., Peters F.T. (eds.) 16. GTFCh-Symposium Gesellschaft für Toxikologische und Forensische Chemie, Toxichem + Krimtech. Peer-reviewed.
[serval:BIB_4711B8DB7D32]
 
Pharmacodynamic interaction between SSR180575 and enalapril on the blood pressure response to angiotensin-I challenges in healthy normotensive male volunteers
Livio F., Buclin T., Nussberger J., Appenzeller M., Gaud C., Duluc M.E., Pinquier J.L., Biollaz J., 2009., Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Edinburgh p. 83 dans Basic and Clinical Pharmacology and Toxicology.
[serval:BIB_C2790E8478F7]
 
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M., Di Iulio J., Buclin T., Rotger M., Lubomirov R., Cavassini M., Fayet A., Décosterd L.A., Eap C.B., Biollaz J. et al., 2009. Clinical Pharmacology and Therapeutics, 85 (5) pp. 485-494. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_09C3908EC60D]
 
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N., Csajka C., Pascual M., Manuel O., Lamoth F., Meylan P., Aubert J.D., Venetz J.P., Soccal P., Decosterd L.A. et al., 2009. Antimicrobial agents and chemotherapy, 53 (7) pp. 3017-23.
[DOI][WoS][Pmid][serval:BIB_6BCA0E0A0A40]
 
Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
Lamoth F., Buclin T., Csajka C., Pascual A., Calandra T., Marchetti O., 2009. Antimicrobial Agents and Chemotherapy, 53 (2) pp. 785-787. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3C81678B0325]
 
Referrals of cancer versus non-cancer patients to a palliative care consult team: do they differ?
Cantin B., Rothuisen L.E., Buclin Thierry, Pereira J., Mazzocato Claudia, 2009. Journal of Palliative Care, 25 (2) pp. 92-99.
[WoS][Pmid][serval:BIB_447E052AF000]
The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube.
Podilsky G., Berger-Gryllaki M., Testa B., Buclin T., Roulet M., Pannatier A., 2009. European Journal of Clinical Pharmacology, 65 (5) pp. 435-442.
[URN][DOI][WoS][Pmid][serval:BIB_40E54B8E7B5F]
 
Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N., Decosterd L.A., Meylan P., Pascual M., Biollaz J., Buclin T., 2009. Clinical Pharmacokinetics, 48 (6) pp. 399-418. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB0583FDF1A4]
2008
 
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.
Fayet A., Béguin A., de Tejada B.M., Colombo S., Cavassini M., Gerber S., Eap C.B., Telenti A., Buclin T., Biollaz J. et al., 2008/08. Therapeutic drug monitoring, 30 (4) pp. 511-522. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_14181C037D30]
 
Antidepressants for the treatment of chronic pain.
Verdu B., Decosterd I., Buclin T., Stiefel F., Berney A., 2008. Drugs, 68 (18) pp. 2611-2632. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB3ECEE27130]
 
Calibration of fractionated metanephrines in urine: still an issue?
Grouzmann E., Mathian B., Buclin T., 2008. Clinical Chemistry, 54 (10) pp. 1738-1739.
[DOI][WoS][Pmid][serval:BIB_7FB0AC676C56]
 
Disposition of oral valganciclovir during continuous renal replacement therapy in two lung transplant recipients
Perrottet Nancy, Robatel Corinne, Meylan Pascal, Pascual Manuel, Venetz Jean-Pierre, Aubert John-David, Berger Mette M., Decosterd Laurent A., Biollaz Jerome, Buclin Thierry, 2008. p. 566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
[WoS][serval:BIB_90C644532B8E]
Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients.
Perrottet N., Robatel C., Meylan P., Pascual M., Venetz J.P., Aubert J.D., Berger M.M., Decosterd L.A., Buclin T., 2008. Journal of Antimicrobial Chemotherapy, 61 (6) pp. 1332-1335.
[URN][DOI][WoS][Pmid][serval:BIB_FB953C5B3D78]
Dépistage des substances d'abus
Widmer N., Buclin T., Augsburger M., 2008. Pharma-Flash, 35 (2-3) pp. 5-11. Peer-reviewed.
[URN][serval:BIB_7E005684AEFD]
 
Efavirenz Dose Adjustment in HIV Patients with Impaired CYP2B6 Function
Csajka C., Cavassini M., Rotger M., Decosterd L. A., Furrer H., Calmy A., Fayet A., Arab-Alameddine M., Widmer N., di Iulio J. et al., 2008. Pharmacotherapy, 28 (9) pp. 215e-216e. Peer-reviewed.
[serval:BIB_B959BE3BFC81]
 
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients.
Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., Bovet P., Bush A.I., Conus P., Copolov D. et al., 2008. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 33 (9) pp. 2187-99. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_57F07E73D442]
 
Hépatite cholestatique persistante sur terbinafine [Terbinafine induced hepatitis with persistent cholestasis]
Gendre Grégoire, Berney Jean-Louis, Buclin Thierry, Morard Isabelle, Fontannaz Jean, 2008. Revue Médicale Suisse, 4 (149) pp. 736-739.
[Pmid][serval:BIB_DE45A5ACEB7D]
 
Is dipeptidylpeptidase IV the missing link in angiotensin-converting enzyme inhibitor--induced angioedema?
Grouzmann E., Buclin T., 2008. Hypertension, 51 (1) pp. 45-7.
[DOI][WoS][Pmid][serval:BIB_A6FECBCB5AC9]
 
Les risques liés à l'utilisation des rétinoïdes topiques pendant la grossesse
Panchaud A., Stah B., Schaefer C., Berlin M., De Santis M., Vial T., Ieri A., Malm H., Eleftheriou G., Rothuizen L.E. et al., 2008. Tribune médicale = Medical Tribune, 14 (Mai 21-22) p. 11.
[serval:BIB_7CB319A8DBDE]
 
Low-dose valganciclovir is efficacious and safe for prophylaxis of cytomegalovirus infection in kidney transplantation
Perrottet Nancy, Manuel Oriol, Venetz Jean-Pierre, Lamoth Frederic, Decosterd Laurent A., Buclin Thierry, Biollaz Jerome, Meylan Pascal, Pascual Manuel, 2008. pp. 565-566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
[WoS][serval:BIB_BA42B5399BF1]
 
Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administration.
Grouzmann E., Buclin T., Biollaz J., 2008. American Journal of Health-System Pharmacists, 65 (3) pp. 226-228. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B5B979919F0C]
 
Médicaments et allaitement: quelques éléments a considérer avant de les juger incompatibles [Drugs and breastfeeding: some facts to consider before deciding they are incompatible]
Panchaud A., Fischer C., Rothuizen L., Buclin T., 2008. Revue Médicale Suisse, 4 (146) pp. 540-545.
[Pmid][serval:BIB_8016F6851F68]
 
Médicaments et allaitement: quelques éléments à considérer avant de les juger incompatibles [Drugs and breastfeeding: some facts to consider before deciding they are incompatible]
Panchaud A., Fischer C., Rothuizen L., Buclin T., 2008. Revue Médicale suisse, 4 (146) pp. 540-545.
[Pmid][serval:BIB_D2B0759CD078]
 
Pharmacovigilance [Pharmacovigilance update]
Livio F., Buclin T., Biollaz J., 2008. Revue Médicale Suisse, 4 (140) pp. 150-154.
[Pmid][serval:BIB_1AC8DF45F435]
 
Pharmacovigilance [Pharmacovigilance update]
Livio F., Buclin T., Biollaz J., 2008. Revue Médicale Suisse, 4 (140) pp. 150-154.
[Pmid][serval:BIB_C927A68F240C]
 
Promotion de la prescription
Buclin Thierry, 2008. pp. 84 p. dans 76e Assemblée Annuelle de la Société Suisse de Médecine Interne, Revue Medicale Suisse.
[serval:BIB_44BD0CA35C4D]
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Widmer N., Decosterd L. A., Leyvraz S., Duchosal M. A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2008. British Journal of Cancer, 98 (10) pp. 1633-1640. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5285F3FECE13]
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1644-1668. Peer-reviewed.
[Pmid][serval:BIB_56FB6F49D00F]
 
Suivi thérapeutique des médicaments (II). La pratique clinique [Therapeutic drug monitoring: clinical practice].
Widmer N., Werner D., Grouzmann E., Eap C.B., Marchetti O., Fayet A., Csajka C., Decosterd L.A., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1649-1660. Peer-reviewed.
[Pmid][serval:BIB_53F56A1C36B3]
 
Tests pharmacogénétiques: bientôt avant chaque prescription [Pharmacogenetic testing: soon before every prescription?]
Buclin T., Colombo S., Biollaz J., 2008. Revue Médicale Suisse, 4 (165) pp. 1666-1670.
[Pmid][serval:BIB_790D0D406387]
 
Topical retinoids exposure during pregnancy.
Panchaud A., Stahl B., Schaefer C., Berlin M., De Santis M., Vial T., Ieri A., Malm H., Eleftheriou G., Buclin T., 2008. pp. e677-e678 dans 9th World Conference on Clinical Pharmacology and Therapeutics, Canadian Journal of Clinical Pharmacology.
[serval:BIB_7618155BC355]
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O., 2008. Clinical Infectious Diseases, 46 (2) pp. 201-211.
[URN][DOI][WoS][Pmid][serval:BIB_0AF2ACCE09D5]
2007
 
Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples
Perrottet N., Beguin A., Meylan P., Pascual M., Manuel O., Buclin T., Biollaz J., Decosterd L. A., 2007/06. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 852 (1-2) pp. 420-9.
[DOI][WoS][Pmid][serval:BIB_531C59A30064]
 
Gluthatione percursor, N-acetyl-cysteine, modulates mimatch negativity generation in schizophrenia patients
Lavoie S., Murray M., Knyazeva M., Bovet P., Buclin T., Conus P., Deppen P., Meuli R., Solida A., Cuenod M. et al., 2007/03. pp. N/A dans 2007.03.9-10, SSN - NCCR Neuro - SSMS joint meeting, Von Roll Areal, University of Bern, Switzerland. Book of abstract P. 96. Poster I19..
[serval:BIB_92F7B7146593]
 
A glutathione precursor, N-acetyl-cysteine, modulates mismatch negativity generation in schizophrenia patients
Lavoie Suzie, Murray Micah M., Knyazeva Maria, Bovet Pierre, Buclin Thierry, Conus Philippe, Deppen Patricia, Meuli Reto, Solida Alessandra, Cuénod Michel et al., 2007. p. 440 dans , Schizophrenia Bulletin. Peer-reviewed.
[DOI][WoS][serval:BIB_BF6D5D38D045]
Acute pain in adults admitted to the emergency room: development and implementation of abbreviated guidelines.
Tamchès E., Buclin T., Hugli O., Decosterd I., Blanc C., Mouhsine E., Givel J.C., Yersin B., 2007. Swiss Medical Weekly, 137 (15-16) pp. 223-227. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_1A54A602F328]
 
Clinical consequences of imatinib plasma concentrations variability in hemato-oncologic patients
Widmer N., Leyvraz S., Duchosal M.A., Rosselet A., Csajka C., Henry H., Debiec-Rychter M., Eap C.B., Biollaz J., Buclin T. et al., 2007. p. 481 dans 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
[WoS][serval:BIB_6B840EC11A9C]
 
Does tenofovir influence efavirenz pharmacokinetics?
Rotger M., Colombo S., Furrer H., Decosterd L., Buclin T., Telenti A., 2007. Antiviral Therapy, 12 (1) pp. 115-8.
[WoS][Pmid][serval:BIB_A7D2AFCBBA6A]
 
Effect of dronedarone on renal function in healthy subjects.
Tschuppert Y., Buclin T., Rothuizen L.E., Decosterd L.A., Galleyrand J., Gaud C., Biollaz J., 2007. British Journal of Clinical Pharmacology, 64 (6) pp. 785-791. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_29365D442E7A]
 
Gliptins.
Grouzmann E., Buclin T., Biollaz J., 2007. Lancet, 369 (9558) p. 269. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C4BF89382E03]
 
Impact of the C2/C6 ratio of high-molecular-weight hydroxyethyl starch on pharmacokinetics and blood coagulation in pigs.
Schramm S., Thyes C., Frascarolo P., Buclin T., Burki M., Fisch A., Burmeister M.A., Asmis L., Spahn D.R., 2007. Anesthesiology, 107 (3) pp. 442-451. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75938732CBB7]
 
Novel starches: single-dose pharmacokinetics and effects on blood coagulation.
Madjdpour C., Thyes C., Buclin T., Frascarolo P., von Roten I., Fisch A., Burmeister M., Bombeli T., Spahn D.R., 2007. Anesthesiology, 106 (1) pp. 132-143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A94B5F296DA1]
 
NPY Y1 receptor is not involved in the hemodynamic response to an acute cold pressor test in mice.
Cavadas C., Waeber B., Pedrazzini T., Grand D., Aubert J.F., Buclin T., Grouzmann E., 2007. Peptides, 28 (2) pp. 315-319. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_844EE50A3071]
 
Oligoanalgesia in the emergency department: short-term beneficial effects of an education program on acute pain.
Decosterd I., Hugli O., Tamchès E., Blanc C., Mouhsine E., Givel J.C., Yersin B., Buclin T., 2007. Annals of emergency medicine, 50 (4) pp. 462-471.
[DOI][WoS][Pmid][serval:BIB_AF2D6A3F434A]
 
Pharmacokinetic and pharmacodynamic assessement of valganciclovir in the prophylaxis and treatment of CMV disease in solid organ transplant patients
Manuel O., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Pascual M., Meylan P., 2007. pp. 9S dans Annual Conference Swiss Society for Paediatrics, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_28547DFCE2DB]
 
Pharmacovigilance et tératovigilance
Livio F., Buclin T., Biollaz J., 2007/01. Revue médicale suisse, 3 (95) pp. 238-242.
[Pmid][serval:BIB_73BD0245A51C]
 
Relations entre les taux plasmatiques d'imatinib et ses effets cliniques
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. dans 14es Journées Franco-Suisses de Pharmacie Hospitalière.
[serval:BIB_3A8230D7BEEB]
 
Relationships between imatinib plasma levels and efficacy
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. pp. 80S dans 75. Jahresversammlung der Schweizerisches Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_04D9A704BCA5]
 
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels.
Widmer N., Rumpold H., Untergasser G., Fayet A., Buclin T., Decosterd L.A., 2007. Leukemia, 21 (7) pp. 1561-2; author reply 1562-4. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7945159811E3]
 
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Pascual A., Nieth V., Calandra T., Bille J., Bolay S., Decosterd L.A., Buclin T., Majcherczyk P.A., Sanglard D., Marchetti O., 2007. Antimicrobial Agents and Chemotherapy, 51 (1) pp. 137-143.
[DOI][WoS][Pmid][serval:BIB_62560DA1D073]
 
Étude des biais sur la dose parentérale d'un nouveau médicament lors d'un essai clinique avec profil cinétique.
Widmer N., Perrottet N., Brunner F., Biollaz J., Buclin T., 2007. pp. 81S dans 75e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_4B9BBCA4E616]
2006
 
Effect of high- and low-molecular-weight low-substituted hydroxyethyl starch on blood coagulation during acute normovolemic hemodilution in pigs
Thyes C., Madjdpour C., Frascarolo P., Buclin T., Burki M., Fisch A., Burmeister M. A., Asmis L., Spahn D. R., 2006/12. Anesthesiology, 105 (6) pp. 1228-37.
[DOI][WoS][Pmid][serval:BIB_DF16BCD32CFB]
 
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
Colombo S., Buclin T., Cavassini M., Decosterd L. A., Telenti A., Biollaz J., Csajka C., 2006/11. Antimicrobial Agents and Chemotherapy, 50 (11) pp. 3801-8.
[DOI][WoS][Pmid][serval:BIB_B3F88281E351]
 
A case of voluntary intoxication with efavirenz and lamivudine
Boscacci R. T., Buclin T., Furrer H., Fux C. A., 2006/06. AIDS, 20 (9) pp. 1352-4.
[DOI][WoS][Pmid][serval:BIB_1655467E3722]
 
Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
Colombo S., Telenti A., Buclin T., Furrer H., Lee B. L., Biollaz J., Decosterd L. A., 2006/06. Therapeutic Drug Monitoring, 28 (3) pp. 332-8.
[DOI][WoS][Pmid][serval:BIB_34514467D3D9]
 
Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial.
Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Boulat O., Hug C., Pilet M., Roulet M., 2006/06. Clinical Nutrition, 25 (3) pp. 418-427. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E4584C2980DA]
 
Generiques et article 38a OPAS: quel impact? [Generic drugs and legal incentives: which impact?]
Livio F., Buclin T., Pannatier A., Biollaz J., 2006/04. Revue Médicale Suisse, 2 (61) pp. 966-9.
[Pmid][serval:BIB_6747553D6285]
 
Ne pas negliger le risque de surtraitement: l'exemple des antiepiteptiques. [Risk of overtreatment: not to be neglected. The example of antiepileptic drugs]
Rothuizen L. E., Buclin T., Reichhart M., Biollaz J., 2006/04. Revue Médicale Suisse, 2 (61) pp. 976-80.
[Pmid][serval:BIB_CDD994234E2B]
 
Attitude de prescription chez la femme enceinte : exemple de prise en charge d'un état dépressif
Panchaud A., Rothuizen L.E., Buclin T., 2006. Swiss Medical Forum = Forum Médical Suisse, 6 (43) pp. 961-964. Peer-reviewed.
[serval:BIB_F9F8EB1B65FD]
 
Effets du cannabis oral et du dronabinol sur la capacité à conduire [Effects of oral cannabis and dronabinol on driving capacity]
Giroud C., Augsburger M., Favrat B., Menetrey A., Pin M.A., Rothuizen L.E., Appenzeller M., Buclin T., Mathieu S., Castella V. et al., 2006. Annales Pharmaceutiques Françaises, 64 (3) pp. 161-172.
[Pmid][serval:BIB_85D07622711E]
 
Exposition intra-utérine aux SSRI et syndrome de sevrage néonatal : un recensement des mères traitées et un suivi du développement psychomoteur de l'enfant sont-ils nécessaires?
Jequier M., Rothuizen L.E., Buclin T., Hohlfeld P., Tolsa J.F., Tabin R., 2006. Paediatrica : Bulletin der Schweizerischen Gesellschaft für Pädiatrie (SGP) = Bulletin de la Société suisse de pédiatrie (SSP), 17 (4) pp. 34-37.
[serval:BIB_1DAD27703468]
 
Les bonnes pratiques dompteront-elles la recherche clinique [Will good clinical practice domesticate human research?]
Buclin T., Burnand B., Biollaz J., 2006. Revue médicale suisse, 2 (61) pp. 992-6.
[Pmid][serval:BIB_DDC805B0D4BC]
 
Malformations cardiaques congénitales sous paroxétine
Panchaud A., Rothuizen L.E., Buclin T., 2006. Journal Suisse de Pharmacie, 144 (8) pp. 292-295.
[serval:BIB_F6F973A994E2]
 
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Colombo S., Buclin T., Décosterd L.A., Telenti A., Furrer H., Lee B.L., Biollaz J., Eap C.B. and , 2006. Clinical pharmacology and therapeutics, 80 (4) pp. 307-18. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_859F62D8CAD6]
 
Pharmacokinetic and pharmacodynamic evaluation of valganciclovir in solid organ transplant patients
Manuel O., Perrottet N., Venetz J.P., Decosterd L.A., Buclin T., Pascual M., Meylan P., 2006. pp. S19 dans 12th International Society for infectious Diseases, International Journal of Infectious Diseases. Peer-reviewed.
[WoS][serval:BIB_C405A5C4A4C2]
 
Pharmacovigitance--pharmaco-epidemiologie. [Trends in drug therapy]
Livio F., Buclin T., Biollaz J., 2006/01. Revue Médicale Suisse, 2 (48) pp. 155-9.
[Pmid][serval:BIB_A06661C6BF04]
 
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. British journal of clinical pharmacology, 62 (1) pp. 97-112. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6058765DDE09]
 
Relations entre la pharmacocinétique de population de l'imatinib et l'alpha-1-glycoproteine acide chez des patients hémato-oncologiques
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. dans 13es Journées Franco-Suisses de Pharmacie Hospitalière.
[serval:BIB_54B5CDF331B9]
 
Relationship between imatinib population pharmacokinetics and alpha-1-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. pp. 71S dans 74e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_5CB9DE6BA9E2]
 
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures
Colombo S., Buclin T., Franc C., Guignard N., Khonkarly M., Tarr P. E., Rochat B., Biollaz J., Telenti A., Decosterd L. A. et al., 2006. Antiviral Therapy, 11 (1) pp. 53-62.
[WoS][Pmid][serval:BIB_B50E136DB0CD]
 
Troubles anxieux provoqués par le cannabis: sont-ils explicables par des différences de métablisme ou par une vulnérabilité génétique différenciée aux effets psychotropes des cannabinoïdes
Giroud C., Castella V., Favrat B., Rothuizen L.E., Appenzeller M., Buclin T., Mangin P., Augsburger M., 2006. Annales de Toxicologie Analytique, XVIII (3) pp. 185-186. Peer-reviewed.
[serval:BIB_11D814EDF229]
 
Étude des biais sur la dose parentérale d'un nouveau médicament lors d'un essai clinique avec profil cinétique
Widmer N., Perrottet N., Brunner F., Biollaz J., Buclin T., 2006. p. 22 dans Gemeinsamer Kongress der Gesellschaft Schweizerischer Amt- und Spitalapotheker (GSASA) und Schweizerische Gesellschaft für Spitalhygiene (SGS) = Congrès annuel de la Société Suisse des Pharmaciens de l'Administration et des Hôpitaux (GSASA) et de la Société Suisse d'Hygiène Hospitalière (SSHH), GSASA Journal. Peer-reviewed.
[serval:BIB_F2ADD7100F86]
2005
 
Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo
Colombo S., Soranzo N., Rotger M., Sprenger R., Bleiber G., Furrer H., Buclin T., Goldstein D., Decosterd L., Telenti A., 2005/09. Pharmacogenetics and Genomics, 15 (9) pp. 599-608.
[DOI][WoS][Pmid][serval:BIB_B3A8434770B5]
 
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
Colombo S., Beguin A., Telenti A., Biollaz J., Buclin T., Rochat B., Decosterd L. A., 2005/05. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 819 (2) pp. 259-76.
[DOI][WoS][Pmid][serval:BIB_6FC687BADC2D]
 
Polypathologies: faut-il tout traiter? [Multiple diseases: should we treat them all?]
Biollaz J., Buclin T., 2005/04. Revue Médicale Suisse, 1 (14) pp. 941-7.
[Pmid][serval:BIB_DAC38353EF10]
 
Regards recents sur la barriere hemato-encephalique. [The blood-brain barrier: recent insights]
Buclin T., Biollaz J., 2005/04. Revue Médicale Suisse, 1 (14) pp. 959-63.
[Pmid][serval:BIB_8E8C04B12557]
 
The importance of assessing the dose actually administered in pharmacokinetic trials
Buclin T., Perrottet N., Biollaz J., 2005/04. Clinical Pharmacology and Therapeutics, 77 (4) pp. 235-40.
[DOI][WoS][Pmid][serval:BIB_6EF42FD57DFC]
Two cases of "cannabis acute psychosis" following the administration of oral cannabis.
Favrat B., Ménétrey A., Augsburger M., Rothuizen L.E., Appenzeller M., Buclin T., Pin M., Mangin P., Giroud C., 2005/04/01. BMC psychiatry, 5 p. 17. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_50A330F58CDE]
Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
Ménétrey A., Augsburger M., Favrat B., Pin M.A., Rothuizen L.E., Appenzeller M., Buclin T., Mangin P., Giroud C., 2005. Journal of Analytical Toxicology, 29 (5) pp. 327-338. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A94B2E9DBD5F]
 
Dietary supplementation with omega-3 in cystic fibrosis patients
Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Hug C., Pilet M., Roulet M., 2005. pp. S88 dans 28th European Cystic Fibrosis Conference, Journal of Cystic Fibrosis. Peer-reviewed.
[serval:BIB_685CFB9F9BDB]
 
Glossaire de pharmacologie clinique .
Buclin T., Desmeules J., Fattinger K., Krähenbühl S., Kupferschmidt H., 2005. pp. 324-334 dans Bases de la Thérapeutique Médicamenteuse., Documed S.A.
[serval:BIB_38445]
 
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B. L., Keiser O., Biollaz J., Decosterd L., Telenti A., 2005/01. Pharmacogenetics and Genomics, 15 (1) pp. 1-5.
[Pmid][serval:BIB_664B41A07499]
 
Interactions médicamenteuses: implication des systèmes de transport rénaux
Buclin T., Desmeules J., Fattinger K., Krähenbühl S., Kupferschmidt H., 2005. 218-226.
[serval:BIB_A7113283554D]
 
Médicaments, grossesse et allaitement
Buclin T., Desmeules J., Fattinger K., Krähenbühl S., Kupferschmidt H., 2005. 253-262.
[serval:BIB_733E0D2B5550]
 
Pharmakologie und Toxikologie: «Therapeutic Drug Monitoring» (TDM) - der Weg zu einer massgeschneiderten medikamentösen Behandlung
Buclin T., Decosterd L.A., 2005. Swiss Medical Forum = Forum Médical Suisse, 5 (51-52) pp. 1301-1303.
[serval:BIB_AD7AA1C467F8]
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 116-117 dans 7th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
[serval:BIB_3529293D5FE2]
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 63S dans 73e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_5746C1EDC479]
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
Fellay J., Marzolini C., Decosterd L., Golay K.P., Baumann P., Buclin T., Telenti A., Eap C.B., 2005. European journal of clinical pharmacology, 60 (12) pp. 865-73. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7E60EAA242E4]
2004
 
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
Csajka C., Marzolini C., Fattinger K., Decosterd L. A., Telenti A., Biollaz J., Buclin T., 2004/09. Antimicrobial Agents and Chemotherapy, 48 (9) pp. 3226-32.
[DOI][WoS][Pmid][serval:BIB_1C445DFD3180]
Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient.
Robatel C., Rusca M., Padoin C., Marchetti O., Liaudet L., Buclin T., 2004/07. The Journal of Antimicrobial Chemotherapy, 54 (1) pp. 269-270. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A37F4C59DB8]
 
Bases de donnees informatiques d'interactions medicamenteuses: quel choix? [Drug interaction computer programs: which choice?]
Perrin Y., Buclin T., Biollaz J., 2004/06. Schweizerische Rundschau fur Medizin Praxis, 93 (23) pp. 991-6.
[Pmid][serval:BIB_24DFE4D37426]
 
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L. A., Stupp R., 2004/06. Clinical Cancer Research, 10 (11) pp. 3728-36.
[DOI][WoS][Pmid][serval:BIB_3B2D8C83B78B]
 
Le retrait d'un medicament pour raison de securite: Processus et communication. [Withdrawal of a drug from the market for safety reasons: process and communication]
Genton A., Buclin T., 2004/05. Schweizerische Rundschau fur Medizin Praxis, 93 (19) pp. 797-801.
[Pmid][serval:BIB_988ABC7AF711]
 
CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene.
Eap C.B., Fellay J., Buclin T., Bleiber G., Golay K.P., Brocard M., Baumann P., Telenti A., 2004/04. Pharmacogenetics, 14 (4) pp. 255-260. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0DA344954504]
 
Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
Widmer N., Beguin A., Rochat B., Buclin T., Kovacsovics T., Duchosal M. A., Leyvraz S., Rosselet A., Biollaz J., Decosterd L. A., 2004/04. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 803 (2) pp. 285-292. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AC0838E2602]
 
Antalgie aiguë aux urgences: impact d'un projet qualité avec recommandations de pratique
Tamchès E., Buclin T., Blanc C., Decosters I., Mouhsine E., Givel JC., Hugli O., Yersin B., 2004. dans Congrès annuel de la Société Suisse de Médecine Interne_Présentation orale.
[serval:BIB_96924231BB22]
 
DTC: nouvel essor pour un ancien dopant
Buclin T., Biollaz J., 2004. Médecine et Hygiène, 62 (2476) pp. 677-681.
[serval:BIB_484AC50253E4]
Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.
Abriel H., Schläpfer J., Keller D.I., Gavillet B., Buclin T., Biollaz J., Stoller R., Kappenberger L., 2004. Swiss Medical Weekly, 134 (47-48) pp. 685-694. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_7731F4C93DCE]
Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.
Eap C.B., Buclin T., Cucchia G., Zullino D., Hustert E., Bleiber G., Golay K.P., Aubert A.C., Baumann P., Telenti A. et al., 2004. European journal of clinical pharmacology, 60 (4) pp. 237-46. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9381D46D9A28]
Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects
Eap C.B., Buclin T., Hustert E., Bleiber G., Golay K.P., Aubert A.C., Baumann P., Telenti A., Kerb R., 2004. European journal of clinical pharmacology, 60 (4) pp. 231-236. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C414875FF528]
 
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini Catia, Paus Erik, Buclin Thierry, Kim Richard B., 2004. Clinical Pharmacology and Therapeutics, 75 (1) pp. 13-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_111D08D8358F]
Prescription médicamenteuse dans les EMS vaudois
Lucas Edouard, Martin Yves, Cuttelod Serge, Buclin Thierry, 2004. 129 (Raisons de santé ; 91), Lausanne: CHUV, Division de pharmacologie et toxicologies cliniques.
[serval:BIB_5F8B8D34B5D9]
 
Transports rénaux de médicaments : mécanismes et potentiel d'interactions
Buclin T., Biollaz J., Diézi J., 2004. Médecine et Hygiène, 62 (2476) pp. 682-692.
[serval:BIB_04F589412A59]
2003
 
Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients
Robatel C., Decosterd L. A., Biollaz J., Eckert P., Schaller M. D., Buclin T., 2003/12. Journal of Clinical Pharmacology, 43 (12) pp. 1329-40.
[DOI][WoS][Pmid][serval:BIB_FB70FDC0E665]
 
Functional consequence of MDR1 expression on imatinib intracellular concentrations
Widmer N., Colombo S., Buclin T., Decosterd L. A., 2003/08. Blood, 102 (3) p. 1142. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BCDCDDB61B48]
 
Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days
Vouillamoz-Lorenz S., Buclin T., Lejeune F., Bauer J., Leyvraz S., Decosterd L. A., 2003/06. Anticancer Research, 23 (3C) pp. 2757-65.
[WoS][Pmid][serval:BIB_00344D20AA08]
 
Composition and cost of drugs stored at home by elderly patients.
Wasserfallen J.B., Bourgeois R., Büla C., Yersin B., Buclin T., 2003. Annals of Pharmacotherapy, 37 (5) pp. 731-737. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AEA0497DA96]
 
Evaluation of online telemonitoring of drug adherence: a pilot randomized, controlled study in patients with epilepsy.
Schneider M.P, Despland P.A, Buclin Th., Burnier M, 2003. The Journal on Information Technology in Healthcare, 1(6) pp. 419-435.
[serval:BIB_29991]
 
Major depressive disorder in the general hospital: adaptation of clinical practice guidelines
Voellinger Rachel, Berney Alexandre, Baumann Pierre, Annoni Jean-Marie, Bryois Christian, Buclin Thierry, Büla Christophe, Camus Vincent, Christin Laurent, Cornuz Jacques et al., 2003. General Hospital Psychiatry, 25 (3) pp. 185-193. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_802520ED427C]
 
NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios
Nyeki A., Buclin T., Biollaz J., Decosterd L. A., 2003/01. British Journal of Clinical Pharmacology, 55 (1) pp. 62-7.
[DOI][WoS][Pmid][serval:BIB_0295C4681187]
 
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C., Marzolini C., Fattinger K., Décosterd L.A., Fellay J., Telenti A., Biollaz J., Buclin T., 2003. Clinical pharmacology and therapeutics, 73 (1) pp. 20-30. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39A9FD8E09B3]
2002
 
Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers
Buclin T., Cosma Rochat M., Burckhardt P., Azria M., Attinger M., 2002/08. Journal of Bone and Mineral Research, 17 (8) pp. 1478-85.
[DOI][WoS][Pmid][serval:BIB_C57FB378903F]
 
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery
Marzolini C., Beguin A., Telenti A., Schreyer A., Buclin T., Biollaz J., Decosterd L. A., 2002/07. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 774 (2) pp. 127-40.
[DOI][WoS][Pmid][serval:BIB_FE146774859E]
 
The interpretation of secondary blood markers can get hazardous in case of a discontinuous rhEPO treatment
Robinson N., Saugy M., Buclin T., Gremion G., Mangin P., 2002/06. Haematologica, 87 (6) pp. ELT28.
[Pmid][serval:BIB_D0CCFB7B5480]
 
Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC.
Robatel C., Buclin T., Eckert P., Schaller M.D., Biollaz J., Decosterd L.A., 2002. Journal of pharmaceutical and biomedical analysis, 29 (1-2) pp. 17-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C053F7A8E078]
 
Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients.
Doser N., Kübli S., Telenti A., Marzolini C., Chave J.P., Feihl F., Buclin T., Pannatier A., Darioli R., Nicod P. et al., 2002. AIDS, 16 (14) pp. 1982-3. Peer-reviewed.
[Pmid][serval:BIB_477361CA79FF]
 
Expérimentation humaine et essais cliniques contrôlés
Buclin T., Biollaz J., 2002. Le Fait Médical, 51 pp. 2-3.
[serval:BIB_47EEC4823BAA]
 
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence
Eap C.B., Buclin T., Baumann P., 2002. Clinical pharmacokinetics, 41 (14) pp. 1153-1193. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_520812777D83]
 
Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.
Csajka C., Buclin T., Fattinger K., Brunner H.R., Biollaz J., 2002. Clinical pharmacokinetics, 41 (2) pp. 137-52. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3A11C82CE346]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University